| Aug 5 |
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 5 |
Arcturus Therapeutics: Q2 Earnings Snapshot
|
| Aug 5 |
Arcturus Therapeutics GAAP EPS of -$0.64 beats by $1.07, revenue of $49.86M beats by $27.63M
|
| Aug 4 |
Arcturus Therapeutics Q2 2024 Earnings Preview
|
| Aug 1 |
Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
|
| Jul 18 |
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
|
| Jul 1 |
Arcturus to file IND for phase 2 study for cystic fibrosis candidate
|
| Jul 1 |
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
|
| Jun 26 |
Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rival
|
| Jun 20 |
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
|
